The FDA Drug Shortages Database is the U.S. Food and Drug Administration’s public listing of prescription drugs currently in shortage nationwide, along with drugs recently resolved from shortage status. It is maintained by FDA’s Center for Drug Evaluation and Research (CDER) Drug Shortage Staff and is searchable at accessdata.fda.gov/scripts/drugshortages, with background and policy context at fda.gov/drugs/drug-safety-and-availability/drug-shortages. For research administrators, the list is not just a pharmacy-operations concern: it is a real signal for continuity risk on any trial that depends on a marketed drug as a comparator, background/standard-of-care therapy, or rescue medication, and it intersects with the same manufacturing-quality issues that can affect investigational product (IMP) supply chains more broadly.
What counts as a shortage, by FDA’s definition
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), FDA considers a drug to be in shortage when, at a national level, aggregate manufacturer supply is not meeting current demand, or is not forecasted to meet projected demand. This is a supply-and-demand definition, not a definition tied to a single manufacturer’s discontinuation notice or a single region’s stock-out — a product can remain off the shortage list even if one hospital pharmacy or one supplier is temporarily out, provided national supply overall is adequate, and conversely a drug can be listed even when some distributors still have stock, if FDA’s aggregate assessment indicates demand is outpacing available supply.
How a drug gets added to the list
Most of the information that triggers a shortage listing comes directly from manufacturers, not from downstream reports of empty shelves. FDA’s Drug Shortage Staff works with industry on an ongoing basis, and manufacturers are required by statute to notify FDA in advance of certain supply disruptions:
- Section 506C of the FD&C Act (added by Title X of the FDA Safety and Innovation Act, FDASIA, in 2012, with FDA’s implementing final rule effective 8 July 2015) requires applicants and manufacturers of certain prescription drugs and biologics — specifically those that are life-supporting, life-sustaining, or intended for use in preventing or treating a debilitating disease or condition, including products used in emergency care or critical surgery — to notify FDA of a permanent discontinuance or a manufacturing interruption likely to cause a meaningful supply disruption.
- Notification is required at least six months in advance where possible; where six months’ notice genuinely isn’t feasible, notification is required as soon as practicable and no later than five business days after the discontinuance or interruption.
- Beyond the mandatory 506C category, manufacturers of other drugs, along with distributors, providers, and professional associations, can also alert FDA to emerging supply problems — from GMP or quality-control failures found during inspection, to raw-material and active-pharmaceutical-ingredient (API) constraints, to sudden demand spikes (public health emergencies, off-label use surges, a competitor’s product being pulled from the market) and voluntary or FDA-initiated recalls.
- FDA can also issue a formal noncompliance letter to a firm that fails to meet its 506C notification obligation, which is itself a public signal that a shortage-relevant disruption may be underway.
Once FDA has credible information from any of these channels, the Drug Shortage Staff assesses the overall national supply-demand picture — not just one manufacturer’s status — before the product is listed as a current shortage.
How a drug is removed (marked resolved)
A listing is updated to “resolved” once FDA determines, generally in coordination with the manufacturer(s), that supply has recovered enough to meet national demand. This can mean the original manufacturer has restored production, an alternative manufacturer of the same or a therapeutically equivalent product has expanded supply, or FDA has taken a supply-side action (such as temporarily permitting import of a foreign-approved equivalent) that closes the gap. The database preserves resolved shortages for a period after resolution, which is useful for research administrators reviewing whether a comparator drug’s supply has actually stabilized versus merely dipped below the reporting threshold.
Why this matters for clinical trial supply continuity
Most investigational products themselves are not commercially marketed and so don’t appear on the FDA shortage list directly — IMP supply is managed through the trial’s own manufacturing, distribution, and accountability chain (see our guide on clinical trial supply management). But the shortage list is still directly relevant to trial operations in several concrete ways:
- Comparator and background-therapy drugs. Many protocols specify an FDA-approved, commercially sourced drug as the active comparator, standard-of-care background therapy, or rescue medication. If that product goes into shortage, sites may be unable to source it through normal pharmacy channels, forcing a protocol amendment, an alternate sourcing plan, or in some cases a pause in enrollment at affected sites.
- Shared manufacturing risk. A shortage driven by a GMP or quality finding at a contract manufacturing site is a signal worth checking against your own IMP supply chain if the sponsor uses the same facility, active ingredient supplier, or fill-finish line for both the marketed comparator and the investigational drug — see our guide on Good Manufacturing Practice (GMP) for how quality failures propagate into supply disruptions.
- Safety and rescue medication access. Trials with defined safety monitoring plans sometimes specify a rescue or emergency-use drug that must be readily available at site. A shortage of that product is a protocol-deviation and patient-safety risk that should be flagged through the trial’s normal pharmacovigilance and safety-reporting channels, not treated purely as a logistics problem.
- Phase-specific exposure. Later-phase trials (see our guide on clinical trial phases) are more likely to rely on marketed comparators at scale across many sites, which increases exposure to a national shortage relative to an early-phase, single-product study.
Research administrators overseeing multi-site or comparator-dependent trials benefit from periodically checking the FDA Drug Shortages Database for any product named in the protocol’s comparator, background-therapy, or rescue-medication provisions, and building a documented contingency plan (alternate sourcing, therapeutic substitution pathway, or protocol amendment trigger) before a shortage actually forces the issue.
Frequently asked questions
Is the FDA shortage list the same as a drug recall list?
No. A shortage reflects a supply-demand imbalance and can result from a recall, but most recalls do not cause a national shortage, and most shortages are not caused by a recall. FDA maintains recalls separately through its enforcement and recall reporting channels.
Does an investigational drug ever appear on the FDA shortage list?
Not directly. The shortage list covers approved, commercially marketed prescription drugs and biologics. An unapproved investigational product’s supply is tracked through the sponsor’s own IMP accountability system, not the public FDA database — though the underlying causes (API shortages, GMP findings, contract manufacturer disruption) can affect both simultaneously if supply chains overlap.
How current is the database?
FDA updates the database on an ongoing basis as new information from manufacturers and other sources comes in; it is not a static or periodically-batched list. Research administrators should treat a point-in-time check as a snapshot and re-check before finalizing any sourcing or amendment decision tied to it.
Who at FDA maintains the shortage list?
The Drug Shortage Staff within the Center for Drug Evaluation and Research (CDER) maintains the database and coordinates with manufacturers on prevention and mitigation; biologics-related shortages involve coordination with the Center for Biologics Evaluation and Research (CBER) as applicable.
